TrialThe Journal of antimicrobial chemotherapy2019

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Amesika N Nyaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.